{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"Azacitidine given at low but increasing doses up to 50mg/m2 twice a week. Maximum tolerated dose reported.","groups":[{"description":"Patients receive azacitidine subcutaneously once or twice weekly and oral dexamethasone once weekly starting on day 1. Patients also receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nazacitidine: Given SC\n\nlenalidomide: Given orally\n\ndexamethasone: Given orally\n\nDNA methylation analysis: Correlative studies\n\ngene expression analysis: Correlative studies\n\nbone marrow aspiration: Correlative studies\n\nimmunohistochemistry staining method: Correlative studies\n\nreverse transcriptase-polymerase chain reaction: Correlative studies\n\nflow cytometry: Correlative studies","id":"OG000","title":"Arm A - Azacitidine/Lenalidomide/Dexamethasone"},{"description":"Patients receive azacitidine subcutaneously once or twice weekly and oral dexamethasone once weekly starting on day 1. Patients also receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nazacitidine: Given SC\n\nlenalidomide: Given orally\n\ndexamethasone: Given orally\n\nDNA methylation analysis: Correlative studies\n\ngene expression analysis: Correlative studies\n\nbone marrow aspiration: Correlative studies\n\nimmunohistochemistry staining method: Correlative studies\n\nreverse transcriptase-polymerase chain reaction: Correlative studies\n\nflow cytometry: Correlative studies","id":"OG001","title":"Arm B - CKD Azacitidine/Lenalidomide/Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Participants in phase 1 portion of study","reportingStatus":"POSTED","timeFrame":"During the first 28-day cycle","title":"Phase I: Highest Tolerated Low Dose (HTLD)","type":"PRIMARY","unitOfMeasure":"mg/m^2"}